CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa.

"Declaration of interests The authors declare no competing interests. W.W. is the founder of Branca Bunús, a UCD startup company that manufactures branched polymers for gene delivery and in which Xianqing W. is involved in collaborative research projects."

"This research was supported by the Chinese Government–China Scholarship Council (CSC202008300001) and 10.13039/501100001602Science Foundation Ireland funded project 19/FFP/6522-Frontiers for the Future Award (Republic of Ireland). The authors would like to thank Dr. Alfonso Blanco, director of the Flow Cytometry Core facility in the University College Dublin (UCD) Conway Institute for his assistance in guiding the flow cytometry work, the core technologist at the UCD Conway Genomics Core for her assistance in guiding the qRT-PCR work, Dr. Alexander Nyström (University of Freiburg, Freiburg, Germany) for the donation of the rabbit anti-C7 antibody used in this project, and Dr. Fernando Larcher (CIEMAT, Madrid, Spain) for the donation of the immortalized RDEBK and RDEBF used in this project. The authors would also like to thank Ruth Foley her assistance in revising English grammar and style."